

Affinium Pharmaceuticals (Toronto, ON, Canada) has appointed **Judd Berman** as senior vice president, chemistry. Dr. Berman was most recently director and site head, high-throughput chemistry, and interim site head for computational, analytical, and structural sciences for GlaxoSmithKline's Research Triangle Park, North Carolina facility.

Todd Brady has been appointed Aderis Pharmaceuticals' (Hopkinton, MA) senior director of business development. He was most recently with Xanthus Life Sciences, which he joined after orchestrating its merger with Phenome Sciences, where he served as CEO.

Myogen (Denver, CO) has announced the appointment of **Alene A. Campbell** as vice president of corporate development. Ms. Campbell formerly held the same position at Ribozyme Pharmaceuticals, and served as general manager of Ribozyme's genomics business unit.

Thomas Colatsky has been named vice president, healthcare research at Paradigm Genetics (Research Triangle Park, NC). He was most recently president and CEO of Argolyn Bioscience, and previously served as executive vice president and chief scientific officer at Physiome Sciences.

Robert deGavre has been named to the board of directors and as chair of the audit committee at Corus Pharma (Seattle, WA). Previously, Mr. deGavre served as senior vice president and chief financial officer of Westmark International and vice president and treasurer of Squibb.

Affymax (Palo Alto, CA) has announced the appointment of **Tracy J. Dunn** as vice president of intellectual property. Dr. Dunn joins the company from MedImmune Vaccines, where he served as director of intellectual property.

Oliver S. Fetzer has been named senior vice president of business development and **Robert J. Janosky** has been named vice president of manufacturing at Cubist Pharmaceuticals (Lexington, MA). Dr. Fetzer was most recently vice president and director at Boston Consulting Group, and Mr. Janosky comes to Cubist from Warner-Lambert, where he served as president and general manager.

Arradial (Bedford, MA) has announced the appointment of **Brian Lightbody** to the position of vice president, business development. Before joining Arradial, he was vice president, drug discovery business development at Zymark. Since 1997, he has also served as

chairman for the International Symposium for Laboratory Automation and Robotics (ISLAR).



Christopher U. Missling has been appointed senior vice president of finance and chief financial officer at Curis (Cambridge, MA). He was most recently CFO at Axaron Bioscience, and before that served as head of financial planning at Aventis.

Genmab (Copenhagen, Denmark) has announced the appointment of **Jørgen Petersen** as medical director, effective in November. Dr. Petersen is currently head of the rheumatology clinic in the Finsen Center at Rigshospitalet in Copenhagen.

Syrrx (San Diego, CA) has appointed two senior-level chemists: **Jeffrey A. Stafford** has joined the company as senior director of chemistry and **Daniel B. Kassel** has been named senior director of analytical technologies. Dr. Stafford formerly served as director of chemistry in oncology at GlaxoSmithKline, and Dr. Kassel served as senior director of DuPont Pharmaceuticals Research Labs and director of analytical chemistry at CombiChem.

Paratek Pharmaceuticals (Boston) has named **Donna Supko** director of regulatory affairs. She joins Paratek from Vertex Pharmaceuticals, where she oversaw the inception of clinical trials and regulatory agency interactions.

Daniel G. Welch has been appointed chairman and CEO of Triangle Pharmaceuticals (Durham, NC), succeeding David Barry, founder and former CEO, who passed away in January of this year. From 1987 to 2000, Mr. Welch held various executive positions at Sanofi-Synthelabo including vice president, worldwide marketing and executive vice president and chief operating officer of US operations, and for the past two years has served as president, biopharmaceuticals at Elan.

Patrick Zenner, the immediate past president and CEO of Hoffmann-La Roche, North America, has joined CuraGen's (New Haven, CT) board of directors. Mr. Zenner spent 31 years at Hoffmann-La Roche in positions of increasing responsibility in sales, marketing, healthcare economics, public policy, and governmental affairs. He currently serves on the boards of ArQule, Dendrite International, First Horizon Pharmaceutical, Genta, Geron, Praecis Pharmaceuticals, West Pharmaceutical Services, and Xoma.